BIOCEPT, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-12-11: Form 8-K; Period of report 2019-12-09; Description 8.01 Other Events; Details 8.01.
- 2019-11-13: Form 8-K; Period of report 2019-11-13; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2019-09-27: Form 8-K; Period of report 2019-09-26; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
- 2019-08-12: Form 8-K; Period of report 2019-08-12; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-12-11 | 8-K | 2019-12-09 | 8.01 Other Events | 8.01 On December 9, 2019, Biocept, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Maxim Group LLC, as representative of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale in an underwritten public offering of (i) 19,200,000 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (“Common Stock”), (ii) pre-funded warrants to purchase 5,400,000 shares of Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase an aggregate of 24,600,000 shares of Common Stock (the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants” and, together with the Pre-Funded Warrants and the Shares, the “Securities”). | bioc-8k_20191209.htm |
| 2019-11-13 | 8-K | 2019-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2019, we issued a press release announcing our financial results for the three and nine months ended September 30, 2019. | bioc-8k_20190930.htm |
| 2019-09-27 | 8-K | 2019-09-26 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | bioc-8k_20190926.htm | |
| 2019-08-12 | 8-K | 2019-08-12 | 2.02 Results of Operations and Financial Condition | 2.02 On August 12, 2019, we issued a press release announcing our financial results for the three and six months ended June 30, 2019. | bioc-8k_20190812.htm |
| 2019-07-18 | 8-K | 2019-07-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | bioc-8k_20190715.htm |
| 2019-06-19 | 8-K | 2019-06-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 As discussed below in Item 5.07, Biocept, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved amendments to the Company’s Amended and Restated 2013 Equity Incentive Plan, as amended (the “2013 Plan”), to, among other things, increase the number of shares of the Company’s common stock available for issuance under the 2013 Plan by 2,800,000. 5.07 On June 17, 2019, the Company held the Annual Meeting. | bioc-8k_20190617.htm |
| 2019-05-29 | 8-K | 2019-05-28 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained in Item 1.01 of this Current Report on Form 8-K in relation to the New Warrants and the shares of Common Stock issuable upon the exercise thereof is hereby incorporated by reference into this Item 3.02. 3.03 The information contained above in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 3.03. | bioc-8k_20190528.htm |
| 2019-05-08 | 8-K | 2019-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2019, we issued a press release announcing our financial results for the three months ended March 31, 2019. | bioc-8k_20190331.htm |
| 2019-03-29 | 8-K | 2019-03-28 | 2.02 Results of Operations and Financial Condition | 2.02 On March 28, 2019, we issued a press release announcing our financial results for the three months and year ended December 31, 2018. | bioc-8k_20190328.htm |
| 2019-03-18 | 8-K | 2019-03-15 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 On March 15, 2019, Biocept, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain purchasers identified on the signature pages thereto (the “Purchasers”), pursuant to which the Company offered to the Purchasers, in a registered direct offering, an aggregate of 5,950,000 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”). 3.02 Please see the disclosure regarding the Warrants and the Warrant Shares set forth under Item 1.01, which is incorporated by reference into this Item 3.02. 8.01 On March 15, 2019, the Company issued a press release announcing the offering described in Item 1.01 above, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | bioc-8k_20190315.htm |
| 2019-01-18 | 8-K | 2019-01-18 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On January 18, 2019, Biocept, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain purchasers identified on the signature pages thereto (the “Purchasers”), pursuant to which the Company offered to the Purchasers, in a registered direct offering, an aggregate of 990,000 shares (the “Shares”) of common stock, par value $0.0001 per share. 8.01 On January 18, 2019, the Company issued a press release announcing the offering described in Item 1.01 above, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | bioc-8k_20190118.htm |